Navitoclax, also known as ABT-263, is an orally bioavailable, synthetic small-molecule antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins, which may trigger apoptosis in tumor cells overexpressing Bcl-2, Bcl-XL, and Bcl-w.
Tags: buy Navitoclax (ABT-263) | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | order Navitoclax (ABT-263) | Navitoclax (ABT-263) chemical structure | Navitoclax (ABT-263) in vivo | Navitoclax (ABT-263) in vitro | Navitoclax (ABT-263) formula | Navitoclax (ABT-263) molecular weight